Clinical trial

A Phase I Multicenter, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of Recombinant Vaccinia Virus Expressing the Envelope Glycoproteins of Human Immunodeficiency Virus

NCT00000683

Study summary

ClinicalTrials.gov

A Phase I Multicenter, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of Recombinant Vaccinia Virus Expressing the Envelope Glycoproteins of Human Immunodeficiency Virus

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

BIOLOGICAL · Unmapped registry intervention HIVAC-1e Find medicine records · Find other trials using this name

BIOLOGICAL · Unmapped registry intervention gp160 Vaccine (MicroGeneSys) Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start dateUnknown

PhasePHASE1

Conditions

HIV Infectionsunresolved

Interventions

HIVAC-1eBIOLOGICAL

gp160 Vaccine (MicroGeneSys)BIOLOGICAL

Sponsors & collaborators

National Institute of Allergy and Infectious Diseases (NIAID)lead sponsor

Mapped research locations

RochesterNew York, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00000683 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.